N/A N=20 Veritas Laparoscopic Paraesophageal Hiatal Hernia (PEH) Repair Pilot Trial
Hiatal Hernia
Primary: Recurrence Rate of Hiatal Hernia Rate Based on Upper Gastrointestinal (UGI) Series — 6; 2; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=89 Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
Hereditary Inclusion Body Myopathy · Distal Myopathy With Rimmed Vacuoles · Distal Myopathy, Nonaka Type
Primary: Change From Baseline in UEC Score (Total Force in kg) at Week 48 — -2.25; -2.99 kg — p=0.5387
Phase 3 N=300 S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps
Chronic Sinusitis · Nasal Polyposis
Primary: Nasal Obstruction/Congestion Score — 2.36; 2.35; 1.56; 1.79 units on a scale — p=0.0074
N/A N=67 Nocturnal Mouth Guards, SOVA vs. Standard Acrylic Orthotic; Phase IV
Sleep Bruxism · Tooth Wear
Primary: Total Number of Nights of Splint Wear for Four Months Per Subject. — 93.6; 98.7 nights — p=0.23
Phase 4 N=8 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
Systemic Fungal Infections
Primary: Posaconazole Exposure Described as Area Under the Total Plasma Concentration-time Curve From Time Zero to Infinity After a Single Dose — 17932 ng*h/mL
Phase 4 N=140 Effect of Dexmedetomidine on Emergence Agitation in Children With or Without Tube Insertion Under General Anesthesia
Myringotomy
Primary: Participant's Severity of Emergent Agitation (EA) Using the Pediatric Anesthesia Emergence Delirium (PAED) Scale in PACU (Post-Op Area). — 7; 8 units on a scale
N/A N=23 Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes
Type 2 Diabetes
Primary: Peak Oxygen Consumption (VO2 Peak) — 16.6; 16.1 milliliters per kilogram per minute
Phase 2 N=31 Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus
Asthma
Primary: Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection. — 4.0; 3.3 units on a scale — p=0.59
Phase 3 N=122 Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma
Lymphoma
Primary: Median Progression-free Survival — NA; NA months — p=0.690
Phase 3 N=438 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2) — -1.32; -0.37 percentage of glycosylated haemoglobin — p=<0.001
Phase 2 N=14 Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine
Homocystinuria
Primary: Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient Homocystinuria (CBSDH) Pre and Post Taurine…
Phase 1 N=39 Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
HPV16 Positive · Cervical Intraepithelial Neoplasia (CIN 2/3)
Primary: Number of Participants With Related Serious Adverse Events — 0; 0; 0; 0 Participants
Phase 2 N=70 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
Tumor · Breast Cancer
Primary: Objective Response Rate (ORR) — 28.6; 35 percentage of subjects
Phase 4 N=58 D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
Schizophrenia · Schizoaffective Disorder · Delusional Disorder
Primary: Change in Psychotic Symptoms Rating Scale-Delusions (PSYRATS-D) — 14.26; 11.83; 12.18; 11.91 units on a scale
Phase 2 N=70 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
Chronic Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 90.9; 90.0; 44.4 percentage of participants